BLCO

Over the past 12 months, BLCO's stock price has increased by 9.6%, reaching $16.85 on September 18, 2026, a 10.49% rise from $15.25 on September 22, 2025, with its 52-week range between $13.77 and $18.92. Recent stock-impacting events include the European CE Mark Approval of its SeeLyra™ Femtosecond Laser on September 11, 2026, and new published research on enVista Aspire™ Real World Experience on September 2, 2026. On September 1, 2026, a new survey highlighted women's lack of awareness regarding dry eye as a symptom of perimenopause and menopause. The company announced on August 24, 2026, that two first-in-class eye health therapies would advance to new trials, with combined estimated peak sales exceeding $2 billion. On August 6, 2026, Bausch Health CEO Thomas J. Appio joined the Bausch + Lomb Board of Directors, and the company reaffirmed its guidance. Bausch + Lomb reported broad-based second-quarter growth and raised its full-year 2026 guidance on July 29, 2026, with Q2 CY2026 revenue beating expectations at $1.39 billion (up 9.1% year-on-year), though adjusted EPS of $0.15 missed estimates. The EyeGility™ Inserter Preloaded IOL Delivery System was launched in the United States on July 16, 2026. Earlier, on February 18, 2026, the company announced its fourth-quarter and full-year 2025 financial results, reporting revenue of $1.405 billion for Q4 2025 and $5.101 billion for the full year 2025.